Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
暂无分享,去创建一个
도모유키 이가와 | 담바 시게로 | 슌 시미즈 | 시미즈 | 가나코 다츠미 | 쇼지로 가도노 | 히로키 가와우치 | 가즈히로 오하라 | 마사유키 마츠시타 | 다카시 에무라 | 마사키 가미무라
[1] A. Grossman,et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. , 2012, European journal of endocrinology.
[2] T. Takeuchi,et al. The Japanese experience with biologic therapies for rheumatoid arthritis , 2010, Nature Reviews Rheumatology.
[3] Stephen C Alley,et al. Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.
[4] M. Friedrich,et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells , 2010, Proceedings of the National Academy of Sciences.
[5] R. Landewé,et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.
[6] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[7] P. Kufer,et al. BiTE: Teaching antibodies to engage T-cells for cancer therapy. , 2009, Current opinion in molecular therapeutics.
[8] H. Riechelmann,et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. , 2008, Oral oncology.
[9] G. A. Lazar,et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. , 2007, Drug discovery today.
[10] S. Iida,et al. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.
[11] Janice M Reichert,et al. Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.
[12] Hyo Jeong Hong,et al. Antibody engineering for the development of therapeutic antibodies. , 2005, Molecules and cells.
[13] A. Pavlou,et al. The therapeutic antibodies market to 2008. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] P. Carter,et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.